Idiopathic pulmonary fibrosis (IPF) is a disease of progressive scarring caused by excessive
extracellular matrix (ECM) deposition and activation of α‐SMA‐expressing myofibroblasts …

Pulmonary fibrosis (PF) is a common pathological feature of acute and chronic inflammatory
lung diseases that currently has no effective clinical treatment. Mesenchymal stem cells …

Background The abnormal epithelial-mesenchymal restorative capacity in idiopathic
pulmonary fibrosis (IPF) has been recently associated with an accelerated aging process as …

Fibrocytes are bone marrow-derived, circulating mesenchymal progenitor cells that play a
role in several fibrotic disorders, including lung fibrosis. They are attracted to injured tissue …

Pulmonary fibrosis (PF) is a chronic and ultimately fatal interstitial lung disease of various
causes. The advent of nintedanib and pirfenidone provides treatment options for PF patients …

Epithelial-to-mesenchymal transition (EMT) is a crucial event in the cellular origin of
myofibroblasts that secrete extracellular matrix in the progression of pulmonary fibrosis (PF) …

Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial pneumonia that causes pulmonary
tissue damage and functional impairment. To investigate the effects of cryptotanshinone on …

Background Activating transcription factor 3 (ATF3) is a nuclear protein that is widely
expressed in a variety of cells. It is a stress‐inducible transcription gene and a member of …

Noninvasive and convenient tests to assess pulmonary fibrosis and disease progression in
interstitial lung diseases (ILDs) are currently unavailable. The extracellular matrix molecules …

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible disease of the lung that has
no lasting option for therapy other than transplantation. It is characterized by replacement of …